Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) clinical trials show that antiangiogenic drugs (AADs) fail to achieve the expected efficacy, and combining AAD with chemoradiotherapy does not show superiority over chemoradiotherapy alone. Accumulating evidence suggests the intrinsic AAD resistance in NPC patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qi, Wang, Yujie, Ji, Hong, Sun, Xiaoting, Xie, Sisi, Chen, Longtian, Li, Sen, Zeng, Weifan, Chen, Ruibo, Tang, Qi, Zuo, Ji, Hou, Likun, Hosaka, Kayoko, Lu, Yongtian, Liu, Ying, Ye, Ying, Yang, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391381/
https://www.ncbi.nlm.nih.gov/pubmed/35985991
http://dx.doi.org/10.1038/s41419-022-05171-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391381/
https://www.ncbi.nlm.nih.gov/pubmed/35985991
http://dx.doi.org/10.1038/s41419-022-05171-3

Ejemplares similares